99 research outputs found
Artzney Buchlein der kreutter/ gesamlet durch Johannem Tallat von Vochenberg/ Bey dem aller erfarnesten der Artzney Doctor Schricken zu Wyen
No full textARTZNEY BUCHLEIN DER KREUTTER/ GESAMLET DURCH JOHANNEM TALLAT VON VOCHENBERG/ BEY DEM ALLER ERFARNESTEN DER ARTZNEY DOCTOR SCHRICKEN ZU WYEN
Artzney Buchlein der kreutter/ gesamlet durch Johannem Tallat von Vochenberg/ Bey dem aller erfarnesten der Artzney Doctor Schricken zu Wyen ( - )
Binding ( - )
Title page ( - )
Preface ( - )
Von dem A. Also soltu den Magen erwermen. ( - )
Von dem B. Wer eyne hübsche farbe wil haben. ( - )
Von dem C. für das lenden wee ( - )
Von dem D. Was das haubt reynige. ( - )
Von dem E. Für das darmgicht. ( - )
Von dem F. Was den menschen iung macht. ( - )
Von dem G. Wer ein böss miltz hat. ( - )
Von dem H. Wer faul fleisch habe ynn munde. ( - )
Von dem I. Für das Augen eytter. ( - )
Von dem K. Was Schlangen vertreybe. ( - )
Von dem L. Fur die mutter die nicht an yhrer stat wil bleyben. ( - )
Von dem M. Das einen ein glüend eissen nicht brenne. ( - )
Von dem N. Fur das haupt wee odder fluss. ( - )
Von dem O Welcher nicht dewen mag. ( - )
Von dem P Was die frawen seubert nach der gepurt. ( - )
Von dem Q. Das die fehler ynn den augen vergehen. ( - )
Von dem R. Fur das korren ynn dem bauche ( - )
Von dem S. Was ausbrechen mach. ( - )
Von dem T. Was aus etzet faul fleisch. ( - )
Von dem V. ( - )
Von dem Y Ein laratiue ( - )
Von dem Z. Was lust macht zu essen. ( - )
Index ( - )
Hernach folget ein bewert Recept/ von einem holtz genant Guaicanum ... ( - )
Imprint ( -
The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women
No full textContains fulltext :
117827.pdf (Publisher’s version ) (Closed access)OBJECTIVE:: To describe the pharmacokinetics of tenofovir and emtricitabine in the third trimester of pregnant HIV-infected women and at postpartum. DESIGN:: A nonrandomized, open-label, multicentre phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe. METHODS:: HIV-infected pregnant women treated with the nucleotide/nucleoside analogue reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (TDF 300 mg; equivalent to 245 mg tenofovir disoproxil) and/or emtricitabine (FTC 200 mg) were included in the study. Twenty-four-hour pharmacokinetic curves were recorded in the third trimester (preferably week 33) and postpartum (preferably week 4-6). Collection of a cord blood sample and maternal sample at delivery was optional. Pharmacokinetic parameters were calculated using WinNonlin software version 5.3. Statistical analysis was conducted using SPSS version 16.0. RESULTS:: Thirty-four women were included in the analysis. Geometric mean ratios of third trimester vs. postpartum [90% confidence interval (CI)] were 0.77 (0.71-0.83) for TDF area under the curve (AUC0-24 h); 0.81 (0.68-0.96) for TDF Cmax and 0.79 (0.70-0.90) for TDF C24 h and 0.75 (0.68-0.82) for FTC AUC0-24 h; and 0.87 (0.77-0.99) for FTC Cmax and 0.77 (0.52-1.12) for FTC C24 h. The viral load close to delivery was less than 200 copies/ml in all but one patient, the average gestational age at delivery was 38 weeks. All children were tested HIV-negative and no congenital abnormalities were reported. CONCLUSION:: Although pharmacokinetic exposure of the NRTIs TDF and FTC during pregnancy is approximately 25% lower, this was not associated with virological failure in this study and did not result in mother-to-child transmission
Don\u27t Ignore the Obvious
No full textBilateral vision lossA 51-year old male with bilateral loss of vision. Previous history significant for HIV.VA: Best-corrected, 20/100 OU, declining to 20/400 OU; Color vision: 9.5/10 OUMRIJC virusHAART therapy1. Drake AK, Loy CT, Brew BJ, Chen TCC, Petoumenos K, Li PCK, Wright EJ. Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol 14:418-23, 2007. 2. Wyen C, Lehmann C, Fatkenheuer G, Hoffmann C. AIDS-related progressive multifocalleukoencephalopathy in the era of HAART: report of two cases and review of literature. AIDS Patient Care andSTDs 19:486-94, 2005
Don\u27t Ignore the Obvious (PowerPoint)
No full textBilateral vision lossA 51-year old male with bilateral loss of vision. Previous history significant for HIV.VA: Best-corrected, 20/100 OU, deteriorating to 20/400 OU; Color vision: 9.5/10 OUMRIJC virusHAART therapy1. Drake AK, Loy CT, Brew BJ, Chen TCC, Petoumenos K, Li PCK, Wright EJ. Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol 14:418-23, 2007. 2. Wyen C, Lehmann C, Fatkenheuer G, Hoffmann C. AIDS-related progressive multifocalleukoencephalopathy in the era of HAART: report of two cases and review of literature. AIDS Patient Care andSTDs 19:486-94, 2005
Don\u27t Ignore the Obvious (Presentation Video)
No full textBilateral vision lossA 51-year old male with bilateral loss of vision. Previous history significant for HIV.VA: best-corrected, 20/100 OU, deteriorating to 20/400 OU; Color vision: 9.5/10 OUMRIJC virusHAART therapy1. Drake AK, Loy CT, Brew BJ, Chen TCC, Petoumenos K, Li PCK, Wright EJ. Human immunodeficiency virus-associated progressive multifocal leucoencephalopathy: epidemiology and predictive factors for prolonged survival. Eur J Neurol 14:418-23, 2007. 2. Wyen C, Lehmann C, Fatkenheuer G, Hoffmann C. AIDS-related progressive multifocalleukoencephalopathy in the era of HAART: report of two cases and review of literature. AIDS Patient Care andSTDs 19:486-94, 2005
Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma
No full textPharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women
No full textObjectives: To describe the pharmacokinetics of darunavir in pregnant HIV-infected women in the third trimester and post-partum. Patients and methods: This was a non-randomized, open-label, multicentre, Phase IV study in HIV-infected pregnant women recruited from HIV treatment centres in Europe. HIV-infected pregnant women treated with darunavir (800/100 mg once daily or 600/100 mg twice daily) as part of their combination ART were included. Pharmacokinetic curves were recorded in the third trimester and post-partum. A cord blood sample and maternal sample were collected. The study is registered at ClinicalTrials.gov under number NCT00825929. Results: Twenty-four women were included in the analysis [darunavir/ritonavir: 600/100 mg twice daily (n=6); 800/100 mg once daily (n=17); and 600/100 mg once daily (n=1)]. Geometric mean ratios of third trimester versus post-partum (90% CI) were 0.78 (0.60-1.00) for total darunavir AUC0-tau after 600/100 mg twice-daily dosing and 0.67 (0.56-0.82) for total darunavir AUC0-tau after 800/100 mg once-daily dosing. The unbound fraction of darunavir was not different during pregnancy (12%) compared with post-partum (10%). The median (range) ratio of darunavir cord blood/maternal blood was 0.13 (0.08-0.35). Viral load close to delivery was <300 copies/mL in all but two patients. All children were tested HIV-negative and no congenital abnormalities were reported. Conclusions: Darunavir AUC and Cmax were substantially decreased in pregnancy for both darunavir/ritonavir regimens. This decrease in exposure did not result in mother-to-child transmission. For antiretroviral-naive patients, who are adherent, take darunavir with food and are not using concomitant medication reducing darunavir concentrations, 800/100 mg of darunavir/ritonavir once daily is adequate in pregnancy. For all other patients 600/100 mg of darunavir/ritonavir twice daily is recommended during pregnancy.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
SOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF
No full textSOLAR 12-month European results: Randomized switch trial of CAB plus RPV vs. oral BIC/FTC/TAF
No full textAtazanavir exposure is effective during pregnancy regardless of tenofovir use
No full textItem does not contain fulltextBACKGROUND: We studied the effect of pregnancy on atazanavir pharmacokinetics in the presence and absence of tenofovir. METHODS: This was a non-randomized, open-label, multicentre Phase IV study in HIV-infected pregnant women recruited from European HIV treatment centres. HIV-infected pregnant women treated with boosted atazanavir (300/100 mg or 400/100 mg atazanavir/ritonavir) as part of their combination antiretroviral therapy (cART) were included in the study. 24 h pharmacokinetic curves were recorded in the third trimester and postpartum. Collection of a cord blood and maternal sample at delivery was optional. RESULTS: 31 patients were included in the analysis, 21/31 patients used tenofovir as part of cART. Median (range) gestational age at delivery was 39 weeks (36-42). Approaching delivery 81% (25 patients) had an HIV viral load <50 copies/ml, all <1,000 copies/ml. Least squares means ratios (90% CI) of atazanavir pharmacokinetic parameters third trimester/postpartum were: 0.66 (0.57, 0.75) for AUC0-24h, 0.70 (0.61, 0.80) for Cmax and 0.59 (0.48, 0.72) for C24h. No statistical difference in pharmacokinetic parameters was found between patients using tenofovir versus no tenofovir. None of the patients showed atazanavir concentrations <0.15 mg/l (target for treatment-naive patients). One baby had a congenital abnormality, which was not likely to be related to atazanavir/ritonavir use. None of the children were HIV-infected. CONCLUSIONS: Despite 34% lower atazanavir exposure during pregnancy, atazanavir/ritonavir 300/100 mg once daily generates effective concentrations for protease inhibitor (PI)-naive patients, even if co-administered with tenofovir. For treatment-experienced patients (with relevant PI resistance mutations) therapeutic drug monitoring of atazanavir should be considered to adapt the atazanavir/ritonavir dose on an individual basis.ClinicalTrials.gov number NCT00825929
- …
